Navigation Links
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
Date:11/6/2007

including methotrexate, has been inadequate, and in patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs. In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X-ray, has been demonstrated. In carefully selected patients with RA who have tolerated three initial two-hour infusions of REMICADE, consideration may be given to administering subsequent infusions over a period of not less than one hour.

In the EU, REMICADE is also indicated for the treatment of AS in patients who have severe axial symptoms, elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy. REMICADE is also approved for the treatment of active and progressive PsA in adults when the response to previous disease modifying anti-rheumatic drug therapy has been inadequate. REMICADE should be administered in combination with methotrexate or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated. REMICADE is also approved in the EU for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or have a contraindication to, or are intolerant of other systemic therapy including cyclosporine, methotrexate or PUVA (psoralen plus ultraviolet A light).

In February 2006, REMICADE was approved in the EU for the treatment of moderately to severely active UC in patients who have had an inadequate response to conventional therapy, including corticosteroids and 6-MP or azathioprine, or who are intolerant to or have medical contraindications for such therapies. This approval made REMICADE the first and only biologic therapy approved to treat moderate to severe UC in the EU. In May 2007, REMICADE was indicated for the treatment of severe, active Crohn's disease, in pediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticoste
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy
2. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe
3. Prof. Michel Klein Becomes Chief Scientific Officer at AMVAC
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
7. Genmab Announces 2007 First Half Year Results
8. Pharsight Achieves First License Sale for Public-Source Database
9. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 Research and Markets ... Cell Culture Market 2014-2018" report to their offering.  ... Cell culture is the in vitro growth of plant ... cell studies, and biopharmaceutical production. Cell culture is a ... culture instruments and cell culture consumables are necessary for ...
(Date:7/24/2014)... 24, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... notice on July 18, 2014 from the NYSE ... the CorMedix plan to regain compliance with continued ... the NYSE-MKT is continuing the Company,s listing and ...
(Date:7/24/2014)... , July 24, 2014 WIRB-Copernicus Group ... regulatory and ethical review services for clinical research, ... Formerly a division of Richmond, VA ... leading biosafety and biosecurity consulting firm in ... addition, WCG,s biosafety division – WCG Biosafety™ – ...
(Date:7/24/2014)...  Spherix Incorporated (SPEX) -- an intellectual property development ... property, today announced that the Company will issue a ... on Monday, August 18, 2014 for shareholders. Management has ... Monday, August 18, 2014 to discuss the company,s progress ... Anthony Hayes . Following prepared remarks, ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Spherix Schedules Shareholder Update Call 2
... Inc. (Amex:,SGN) announced that it has filed its Form ... of trading of its common stock,on the American Stock ... trade on AMEX will be Friday, September 12, 2008.,Signalife ... for,quotation on both the Over-The-Counter Bulletin Board and the ...
... Takeda San Francisco Inc.,announced today that Gregory Landes, ... antibody research. Dr. Landes will be responsible for,directing ... Takeda,s antibody IND engine and center of excellence ... experience in the biopharmaceutical,industry and is a great ...
... Sept. 8 NovaVision today announced,that the company ... AdvaMed,2008: The MedTech Conference (http://www.advamed2008.com ), on ... the presentation, which falls in the "Next Generation" ... officer of,NovaVision, will address the increasing use of ...
Cached Biology Technology:Signalife Announces Anticipated Date of Transition to OTCBB 2Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research 2NovaVision CEO Named Presenter at the AdvaMed 2008 Conference 2
(Date:7/24/2014)... new study has identified two factors that characterize ... the production of highly qualified physics teachers. Specifically, ... champion physics teacher education in combination with institutional ... remain viable. Science, Technology, Engineering and Math (STEM) ... the study points the way for institutions seeking ...
(Date:7/24/2014)... 2014 Some sticky research out of York University ... certain species of toxic grass fungus: moose saliva (yes ... Biology Letters , "Ungulate saliva inhibits a grassendophyte mutualism" ... red fescue grass (which hosts a fungus called epichlo ... fungus growth and less toxicity. , "Plants have evolved ...
(Date:7/24/2014)... Albert Einstein College of Medicine of Yeshiva University ... Foundation for Parkinson,s Research to translate a basic science ... discovery project will test chemical compounds on a newly ... that acts on an underlying cause of the disease. ... people manage their symptoms, we are eager to stop ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Moose drool inhibits growth of toxic fungus: York U research 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3
... of the most recent, popular supplements for athletes looking to ... acid called L-arginine. The reason for its popularity ... physiology. "First, L-arginine is a precursor for nitric oxide ... may aid the delivery of important nutrients to working muscles ...
... published this month in the Journal of the American ... Science Center at San Antonio have pinpointed the cancer-fighting potential ... Susan Mooberry, Ph.D., leader of the Experimental Development Therapeutics Program ... of pharmacology at the UT Health Science Center, has been ...
... Researchers at King,s College London have discovered how one ... pave the way for less harmful pain relief medications to ... in the US and Asia as acetaminophen, is a widely-used ... as cold and flu remedies. Although discovered in the ...
Cached Biology News:L-arginine: Supplement tested on fit, athletic men shows no advantage 2L-arginine: Supplement tested on fit, athletic men shows no advantage 3Bat plant could give some cancers a devil of a time 2First study to reveal how paracetamol works could lead to less harmful pain relief medicines 2First study to reveal how paracetamol works could lead to less harmful pain relief medicines 3
...
...
Removes polysaccharide and phenolic inhibitors of PCR; yields DNA greater than 50 kb in length...
Sf9 Insect Cells (Frozen) in Max-XP Medium...
Biology Products: